Wilmington Savings Fund Society FSB Buys 5,361 Shares of Stryker Co. (NYSE:SYK)

Wilmington Savings Fund Society FSB boosted its stake in Stryker Co. (NYSE:SYK - Free Report) by 13.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,795 shares of the medical technology company's stock after acquiring an additional 5,361 shares during the period. Wilmington Savings Fund Society FSB's holdings in Stryker were worth $16,183,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in SYK. Dunhill Financial LLC boosted its holdings in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Centennial Bank AR boosted its holdings in Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock valued at $32,000 after acquiring an additional 48 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in Stryker in the third quarter valued at approximately $36,000. HBW Advisory Services LLC bought a new stake in Stryker in the third quarter valued at approximately $42,000. Finally, Hara Capital LLC bought a new stake in Stryker in the third quarter valued at approximately $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 0.3 %

NYSE SYK traded down $1.15 on Thursday, reaching $375.01. The company had a trading volume of 846,011 shares, compared to its average volume of 1,260,068. Stryker Co. has a 52-week low of $285.79 and a 52-week high of $398.20. The stock has a market capitalization of $142.96 billion, a P/E ratio of 40.23, a P/E/G ratio of 2.89 and a beta of 0.94. The company's fifty day moving average is $372.42 and its 200 day moving average is $354.51. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same period last year, the firm posted $2.46 EPS. The business's revenue was up 11.9% compared to the same quarter last year. Sell-side analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, December 31st. This is a positive change from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. Stryker's dividend payout ratio (DPR) is currently 36.01%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. StockNews.com upgraded Stryker from a "hold" rating to a "buy" rating in a report on Wednesday. Needham & Company LLC increased their price target on Stryker from $409.00 to $442.00 and gave the stock a "buy" rating in a report on Thursday. BTIG Research increased their price target on Stryker from $383.00 to $394.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Citigroup increased their price target on Stryker from $411.00 to $450.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Wells Fargo & Company increased their price target on Stryker from $405.00 to $427.00 and gave the stock an "overweight" rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat, Stryker currently has an average rating of "Moderate Buy" and an average target price of $404.35.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the transaction, the vice president now owns 10,042 shares of the company's stock, valued at $3,685,213.16. The trade was a 42.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,781 shares of company stock valued at $24,612,275 in the last ninety days. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.